UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Oral Treatment with PBI-4425 Decreases Fibrosis in Carbon Tetrachloride (CCL4)-Induced Hepatic Fibrosis Model

Journal of hepatology, 2016, Vol.64 (2), p.S228-S229

2016

Volltextzugriff (PDF)

PBI-4050 Decreases Hepatic Stellate Cell Activation and Ameliorates Fibrosis in Carbon Tetrachloride (CCL4)- Induced Hepatic Fibrosis Model

Journal of hepatology, 2016, Vol.64 (2), p.S707-S707

2016

Volltextzugriff (PDF)

P72 ORAL TREATMENT WITH PBI-4050, A NOVEL FIRST-IN-CLASS ANTI-FIBROTIC COMPOUND, REDUCES HEPATIC FIBROSIS AND HEPATOCELLULAR CARCINOMA

Journal of hepatology, 2014-04, Vol.60 (1), p.S90-S90

2014

Volltextzugriff (PDF)

A Mild Procedure for the Reduction of Pyridine N-Oxides to Piperidines Using Ammonium Formate

Journal of organic chemistry, 2001-07, Vol.66 (15), p.5264-5265

2001

Volltextzugriff (PDF)

PBI-4547 decreases hepatic stellate cell activation via AMPK signaling pathway, and reduces fibrosis in carbon tetrachloride (CCL4)-induced hepatic fibrosis model

Journal of hepatology, 2018-04, Vol.68, p.S408

2018

Volltextzugriff (PDF)

FRI-104 - PBI-4547 decreases hepatic stellate cell activation via AMPK signaling pathway, and reduces fibrosis in carbon tetrachloride (CCL4)-induced hepatic fibrosis model

Journal of hepatology, 2018-04, Vol.68, p.S408-S408

2018

Volltextzugriff (PDF)

SAT-405 - PBI-4050 Decreases Hepatic Stellate Cell Activation and Ameliorates Fibrosis in Carbon Tetrachloride (CCL4)- Induced Hepatic Fibrosis Model

Journal of hepatology, 2016, Vol.64 (2), p.S707-S707

2016

Volltextzugriff (PDF)

THU-281 - Oral Treatment with PBI-4425 Decreases Fibrosis in Carbon Tetrachloride (CCL4)-Induced Hepatic Fibrosis Model

Journal of hepatology, 2016, Vol.64 (2), p.S228-S229

2016

Volltextzugriff (PDF)

B56 SCAR WARS: INSIGHTS INTO MECHANISMS AND TREATMENTS OF PULMONARY FIBROSIS: Pbi-4050 Reduces Inflammatory/fibrotic Markers In A Bleomycin-Induced Lung Fibrosis Model: A Comparative Study With Nintedanib

American journal of respiratory and critical care medicine, 2015-01, Vol.191, p.1

2015

Volltextzugriff (PDF)

B110 NOVEL THERAPIES AND TARGETS IN FIBROSIS: Oral Treatment With Pbi-4050 Reduces Serum And Lung Anti-Inflammatory/fibrotic Biomarkers

American journal of respiratory and critical care medicine, 2016-01, Vol.193, p.1

2016

Volltextzugriff (PDF)

C74 MODELS AND METHODS IN LUNG BIOLOGY: Oral Treatment With Pbi-4050 Reduces Plasminogen Activator Inhibitor-1 (pai-1), Alpha-Smooth Muscle Actin ([alpha]-Sma) and Collagen Expression In Human Fibroblasts And Mice Fibrotic Lungs

American journal of respiratory and critical care medicine, 2016-01, Vol.193, p.1

2016

Volltextzugriff (PDF)

A60 LUNG FIBROSIS: ANIMAL MODELS I: Pbi-4050 Reduces Inflammatory/fibrotic Markers In A Bleomycin-Induced Lung Fibrosis Model: A Comparative Study With Pirfenidone

American journal of respiratory and critical care medicine, 2014-01, Vol.189, p.1

2014

Volltextzugriff (PDF)

B56 SCAR WARS: INSIGHTS INTO MECHANISMS AND TREATMENTS OF PULMONARY FIBROSIS: Oral Treatment With Pbi-4050 Reduces Lung Fibrosis

American journal of respiratory and critical care medicine, 2015-01, Vol.191, p.1

2015

Volltextzugriff (PDF)

Immunostimulant oxidized β-glucan conjugates

International immunopharmacology, 2001-03, Vol.1 (3), p.539-550

2001

Volltextzugriff (PDF)

Synthesis of N-1-oxypyrimidine 1,3-dioxolane and 1,3-oxathiolane nucleosides

Chemical communications (Cambridge, England), 2000-01 (23), p.2311-2312

2000

Volltextzugriff (PDF)

A Convenient, TiCl4/SnCl4-Mediated Synthesis of N-Phenyl or N-Aryl Benzamidines and N-Phenylpicolinamidines

ISRN Organic Chemistry, 2012-07, Vol.2012

2012

Volltextzugriff (PDF)

Renal fibrosis and progression

Nephrology, dialysis, transplantation, 2013-05, Vol.28 (suppl 1), p.i27-i27

2013

Volltextzugriff (PDF)

Enhancement of Th1 type cytokine production and primary T cell activation by PBI-1393

Clinical immunology (Orlando, Fla.), 2007-12, Vol.125 (3), p.318-327

2007

Volltextzugriff (PDF)

Diabetes - basic research

Nephrology, dialysis, transplantation, 2013-05, Vol.28 (suppl 1), p.i50-i51

2013

Volltextzugriff (PDF)

Thioamides: Synthesis, Stability, and Immunological Activities of Thioanalogues of Imreg. Preparation of New Thioacylating Agents Using Fluorobenzimidazolone Derivatives

Journal of medicinal chemistry, 1999-06, Vol.42 (11), p.2046-2052

1999

Volltextzugriff (PDF)

Synergistic anti-tumor activity of a novel immunomodulator, BCH-1393, in combination with cyclophosphamide

International journal of immunopharmacology, 2000-09, Vol.22 (9), p.659-671

2000

Volltextzugriff (PDF)

Synthesis and anti-HIV activity of 1,3-dithiolane nucleosides

Chemical communications (Cambridge, England), 1999-07 (13), p.1245-1246

1999

Volltextzugriff (PDF)

Synthesis and antiviral activities of N-9-oxypurine 1,3-Dioxolane and 1,3-oxathiolane nucleosides

Bioorganic & medicinal chemistry letters, 2000-10, Vol.10 (19), p.2223-2226

2000

Volltextzugriff (PDF)

Thioacylating agents. Use of thiobenzimidazolone derivatives for the preparation of thiotuftsin analogs

Tetrahedron, 1993, Vol.49 (46), p.10489-10500

1993

Volltextzugriff (PDF)

A short synthesis of 4-substituted 1-(hydroxyalkyl)-1H-pyrazolo[3,4-d]pyrimidines

Tetrahedron, 1996-02, Vol.52 (7), p.2271-2278

1996

Volltextzugriff (PDF)

1 – 25 von 151

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(119)
Mit Volltextzugriff
(126)

Publikationsform

Sprache

Englisch
(143)
Französisch
(8)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

Oral Treatment with PBI-4425 Decreases Fibrosis in Carbon Tetrachloride (CCL4)-Induced Hepatic Fibrosis Model

PBI-4050 Decreases Hepatic Stellate Cell Activation and Ameliorates Fibrosis in Carbon Tetrachloride (CCL4)- Induced Hepatic Fibrosis Model

P72 ORAL TREATMENT WITH PBI-4050, A NOVEL FIRST-IN-CLASS ANTI-FIBROTIC COMPOUND, REDUCES HEPATIC FIBROSIS AND HEPATOCELLULAR CARCINOMA

A Mild Procedure for the Reduction of Pyridine N-Oxides to Piperidines Using Ammonium Formate

PBI-4547 decreases hepatic stellate cell activation via AMPK signaling pathway, and reduces fibrosis in carbon tetrachloride (CCL4)-induced hepatic fibrosis model

FRI-104 - PBI-4547 decreases hepatic stellate cell activation via AMPK signaling pathway, and reduces fibrosis in carbon tetrachloride (CCL4)-induced hepatic fibrosis model

SAT-405 - PBI-4050 Decreases Hepatic Stellate Cell Activation and Ameliorates Fibrosis in Carbon Tetrachloride (CCL4)- Induced Hepatic Fibrosis Model

THU-281 - Oral Treatment with PBI-4425 Decreases Fibrosis in Carbon Tetrachloride (CCL4)-Induced Hepatic Fibrosis Model

B56 SCAR WARS: INSIGHTS INTO MECHANISMS AND TREATMENTS OF PULMONARY FIBROSIS: Pbi-4050 Reduces Inflammatory/fibrotic Markers In A Bleomycin-Induced Lung Fibrosis Model: A Comparative Study With Nintedanib

B110 NOVEL THERAPIES AND TARGETS IN FIBROSIS: Oral Treatment With Pbi-4050 Reduces Serum And Lung Anti-Inflammatory/fibrotic Biomarkers

C74 MODELS AND METHODS IN LUNG BIOLOGY: Oral Treatment With Pbi-4050 Reduces Plasminogen Activator Inhibitor-1 (pai-1), Alpha-Smooth Muscle Actin ([alpha]-Sma) and Collagen Expression In Human Fibroblasts And Mice Fibrotic Lungs

A60 LUNG FIBROSIS: ANIMAL MODELS I: Pbi-4050 Reduces Inflammatory/fibrotic Markers In A Bleomycin-Induced Lung Fibrosis Model: A Comparative Study With Pirfenidone

B56 SCAR WARS: INSIGHTS INTO MECHANISMS AND TREATMENTS OF PULMONARY FIBROSIS: Oral Treatment With Pbi-4050 Reduces Lung Fibrosis

Immunostimulant oxidized β-glucan conjugates

Synthesis of N-1-oxypyrimidine 1,3-dioxolane and 1,3-oxathiolane nucleosides

A Convenient, TiCl4/SnCl4-Mediated Synthesis of N-Phenyl or N-Aryl Benzamidines and N-Phenylpicolinamidines

Renal fibrosis and progression

Enhancement of Th1 type cytokine production and primary T cell activation by PBI-1393

Diabetes - basic research

Thioamides: Synthesis, Stability, and Immunological Activities of Thioanalogues of Imreg. Preparation of New Thioacylating Agents Using Fluorobenzimidazolone Derivatives

Synergistic anti-tumor activity of a novel immunomodulator, BCH-1393, in combination with cyclophosphamide

Synthesis and anti-HIV activity of 1,3-dithiolane nucleosides

Synthesis and antiviral activities of N-9-oxypurine 1,3-Dioxolane and 1,3-oxathiolane nucleosides

Thioacylating agents. Use of thiobenzimidazolone derivatives for the preparation of thiotuftsin analogs

A short synthesis of 4-substituted 1-(hydroxyalkyl)-1H-pyrazolo[3,4-d]pyrimidines

Suchergebnisse filtern